KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Payables (2016 - 2025)

Historic Payables for Fulgent Genetics (FLGT) over the last 11 years, with Q3 2025 value amounting to $18.6 million.

  • Fulgent Genetics' Payables fell 817.63% to $18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year decrease of 817.63%. This contributed to the annual value of $18.8 million for FY2024, which is 1349.82% up from last year.
  • Per Fulgent Genetics' latest filing, its Payables stood at $18.6 million for Q3 2025, which was down 817.63% from $19.4 million recorded in Q2 2025.
  • In the past 5 years, Fulgent Genetics' Payables registered a high of $42.9 million during Q2 2022, and its lowest value of $16.5 million during Q4 2023.
  • In the last 5 years, Fulgent Genetics' Payables had a median value of $20.2 million in 2024 and averaged $22.9 million.
  • In the last 5 years, Fulgent Genetics' Payables surged by 51085.81% in 2021 and then plummeted by 4242.31% in 2023.
  • Over the past 5 years, Fulgent Genetics' Payables (Quarter) stood at $20.5 million in 2021, then surged by 40.2% to $28.7 million in 2022, then plummeted by 42.42% to $16.5 million in 2023, then increased by 13.5% to $18.8 million in 2024, then dropped by 1.13% to $18.6 million in 2025.
  • Its Payables was $18.6 million in Q3 2025, compared to $19.4 million in Q2 2025 and $18.7 million in Q1 2025.